Resultados de la búsqueda 11-20 of 257 for ⚡벳365이용법 【위너보증.com / 가입코드 9122】 토지노추천 ⚡

  1. Hematología - Ensayos clínicos - Mayo Clinic

    no prophylactic PLND. Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer. Rochester, Minn. 99mTc-MIP-1404 ...

  2. Hematología - Ensayos clínicos - Mayo Clinic

    no prophylactic PLND. Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer. Scottsdale ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL.

  4. Hematología - Ensayos clínicos - Mayo Clinic

    This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this ...

  5. Medicina cardiovascular - Ensayos clínicos - Mayo Clinic

    To describe the clinical, laboratory, pathologic, imaging findings, therapy and outcomes in all patients with Fibromuscular Dysplasia (FMD) and/or segmental ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...